Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications
May 30 2019 - 7:00AM
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company
focused on improving cardiovascular health, today announced that
Gwen Fisher has joined the company in a newly created role as vice
president of Corporate Communications.
In this role, Fisher will be responsible for leading internal
and external communications for the company. Specifically, she is
charged with advancing and implementing an integrated, progressive
corporate communications strategy designed to educate key
stakeholders about the company and its lead product, Vascepa®.
“Gwen’s deep experience in communications within the
pharmaceutical and biotech industry, across multiple stakeholder
groups and at evolving companies, makes her an ideal fit for
Amarin, especially as we ramp up preparations for the launch of an
anticipated expanded indication for Vascepa,” said John F. Thero,
president and chief executive officer of Amarin. “We are delighted
to have her join our growing team.”
Fisher brings more than 25 years of experience as a business
leader and communications expert, having served in a variety of
leadership positions with Shire, Pfizer, Wyeth and Merck. Her last
position with Shire was heading Global Portfolio Communications,
where she was responsible for internal and external communications
for the global commercial and R&D organizations.
“I’m thrilled to be joining an exciting company like Amarin to
lead the Communications function at such a critical time in the
Company’s growth and transformation,” Fisher said. “The medical
need in the cardiovascular space is great, so I look forward to
collaborating with my new colleagues to educate stakeholders about
the tremendous value Amarin has to offer patients in this
therapeutic area.”
Fisher earned her B.A. in Public Relations from Washington State
University’s Edward R. Murrow College of Communications; and an MBA
from University of California, Los Angeles, Anderson School of
Management.
About Amarin
Amarin Corporation plc. is a rapidly growing, innovative
pharmaceutical company focused on developing therapeutics to
improve cardiovascular health. Amarin’s product development program
leverages its extensive experience in polyunsaturated fatty acids
and lipid science. Vascepa (icosapent ethyl) is Amarin's first
FDA-approved drug and is available by prescription in the United
States, Lebanon and the United Arab Emirates. Amarin’s commercial
partners are pursuing additional regulatory approvals for Vascepa
in Canada, China and the Middle East. For more information about
Amarin, visit www.amarincorp.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding Amarin’s growth and transformation
and impact on improved patient care and anticipated expanded
labelling for Vascepa. These forward-looking statements are not
promises or guarantees and involve substantial risks and
uncertainties. In addition, Amarin's ability to effectively
commercialize Vascepa will depend in part on its ability to
continue to effectively finance its business, efforts of third
parties, its ability to gain regulatory approvals, create market
demand for Vascepa through education, marketing and sales
activities, to achieve market acceptance of Vascepa, to receive
adequate levels of reimbursement from third-party payers, to
develop and maintain a consistent source of commercial supply at a
competitive price, to comply with legal and regulatory requirements
in connection with the sale and promotion of Vascepa and to
maintain patent protection for Vascepa. Among the factors that
could cause actual results to differ materially from those
described or projected herein include the following: uncertainties
associated generally with research and development, clinical trials
and related regulatory approvals; the risk that sales may not meet
expectations and related cost may increase beyond expectations; the
risk that patents may not be upheld in patent litigation and
applications may not result in issued patents sufficient to protect
the Vascepa franchise. A further list and description of these
risks, uncertainties and other risks associated with an investment
in Amarin can be found in Amarin's filings with the U.S. Securities
and Exchange Commission, including its most recent quarterly report
on Form 10-Q. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Amarin undertakes no obligation
to update or revise the information contained in this press
release, whether as a result of new information, future events or
circumstances or otherwise.
Availability of Other Information About
Amarin
Investors and others should note that Amarin communicates with
its investors and the public using the company website
(www.amarincorp.com), the investor relations
website (investor.amarincorp.com), including but
not limited to investor presentations and investor FAQs, Securities
and Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Amarin posts on these
channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media, and others
interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time to
time on Amarin’s investor relations website and may include social
media channels. The contents of Amarin’s website or these channels,
or any other website that may be accessed from its website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
Amarin Contact Information
Media Inquiries: Gwen Fisher Corporate Communications Amarin
Corporation plc In U.S.: +1 (908) 325-0735
pr@amarincorp.com
Investor Relations: Elisabeth Schwartz Investor Relations Amarin
Corporation plc In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com (investor
inquiries)
Lee M. Stern Trout Group In U.S.: +1 (646)
378-2992 lstern@troutgroup.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024